$PPBT News

Purple Biotech Files $200M Mixed Securities Shelf

CORRECTION: Purple Biotech Q1 EPS $(0.09) Beats $(1.06) Estimate

Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240

Purple Biotech Announces New Preclinical Data That Support The Potential Of IM1240, The Company's Lead CAPTN-3 Tri-Specific Antibody

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Announces Formation Of Advisory Board To Support Development of Its CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform

Purple Biotech Regains Compliance with Nasdaq

Purple Biotech Regains Nasdaq Compliance

Purple Biotech Regains Nasdaq Compliance

Purple Biotech Announces CEO Transition

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

Purple Biotech Q4 EPS $19.85 Beats $(3.40) Estimate

Purple Biotech CEO Gil Efron To Step Down In August 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Purple Biotech Announces Plan to Implement ADS Ratio Change

Purple Biotech Announces Plan To Implement ADS Ratio Change From 1-To-200 To 1-To-2,000, Effective March 2nd

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240